Priority review for Shire’s HAE drug

23rd February 2018 Uncategorised 0

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).

More: Priority review for Shire’s HAE drug
Source: News